Centene (CNC) Aktievy
Centene Corporation är ett managed care-företag som tillhandahåller program och tjänster till underförsäkrade familjer och kommersiella organisationer i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
CNC Community Fair Values
Create NarrativeSee what 116 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$95.24
FV
29.7% undervärderad intrinsisk rabatt4.00%
Revenue growth p.a.
18
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Centene Corporation Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$66.99 |
| 52 veckors högsta | US$69.36 |
| 52 veckors lägsta | US$25.08 |
| Beta | 1.1 |
| 1 månads förändring | 1.42% |
| 3 månaders förändring | 21.84% |
| 1 års förändring | 165.73% |
| 3 års förändring | 1.81% |
| 5 års förändring | 3.94% |
| Förändring sedan börsintroduktionen | 4,573.72% |
Senaste nyheter och uppdateringar
Seeking Alpha • Jul 29
Centene's Margin Recovery Keeps The Upside Alive
Summary Centene maintains a Buy rating, reflecting sustained margin improvement, cost control, and capital flexibility supporting a higher valuation multiple. CNC's Q2 adjusted EPS of $2.51 beat estimates by over $1, with operating cash flow up 141% year-over-year to $7.96 billion. Medicaid and Medicare segments show disciplined execution; CNC is prioritizing margin over volume, especially by exiting unprofitable Medicare Advantage plans. Key risks include government rate changes, medical cost inflation, and policy shifts; steady progress and cost discipline are essential for further upside. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jul 28
CNC: Medicaid Margin Recovery Optimism Will Eventually Prove Overstated Despite Recent Upgrades
Centene's fair value estimate has been updated from $40.00 to about $43.26, as analysts lift price targets across the sector, citing constructive Q2 set ups, improving Medicare Advantage and exchange trends, and a more stable policy backdrop that supports moderate adjustments to revenue growth, profit margin assumptions, and future P/E expectations. Analyst Commentary Recent research on Centene points to a broadly constructive tone, with many firms lifting price targets and highlighting improving trends in Medicare Advantage and exchange businesses.
Uppdatering av berättelse • Jul 14
CNC: Medicaid Margin Recovery And Cost Actions Will Shape Balanced Earnings Outlook
Centene's analyst price target has been revised higher, with fair value moving from about $61.83 to $63.78 as analysts highlight more supportive exchange trends, early signs of Medicaid margin recovery, and sector wide adjustments that reflect a steadier policy backdrop. Analyst Commentary Recent research on Centene clusters around a more constructive view on earnings power, supported by exchange trends, Medicare Advantage performance, and early signs of Medicaid margin recovery, while still flagging several execution and policy risks that could affect valuation.Recent updates
Seeking Alpha • Jul 29
Centene's Margin Recovery Keeps The Upside Alive
Summary Centene maintains a Buy rating, reflecting sustained margin improvement, cost control, and capital flexibility supporting a higher valuation multiple. CNC's Q2 adjusted EPS of $2.51 beat estimates by over $1, with operating cash flow up 141% year-over-year to $7.96 billion. Medicaid and Medicare segments show disciplined execution; CNC is prioritizing margin over volume, especially by exiting unprofitable Medicare Advantage plans. Key risks include government rate changes, medical cost inflation, and policy shifts; steady progress and cost discipline are essential for further upside. Read the full article on Seeking AlphaUppdatering av berättelse • Jul 28
CNC: Medicaid Margin Recovery Optimism Will Eventually Prove Overstated Despite Recent Upgrades
Centene's fair value estimate has been updated from $40.00 to about $43.26, as analysts lift price targets across the sector, citing constructive Q2 set ups, improving Medicare Advantage and exchange trends, and a more stable policy backdrop that supports moderate adjustments to revenue growth, profit margin assumptions, and future P/E expectations. Analyst Commentary Recent research on Centene points to a broadly constructive tone, with many firms lifting price targets and highlighting improving trends in Medicare Advantage and exchange businesses.Uppdatering av berättelse • Jul 14
CNC: Medicaid Margin Recovery And Cost Actions Will Shape Balanced Earnings Outlook
Centene's analyst price target has been revised higher, with fair value moving from about $61.83 to $63.78 as analysts highlight more supportive exchange trends, early signs of Medicaid margin recovery, and sector wide adjustments that reflect a steadier policy backdrop. Analyst Commentary Recent research on Centene clusters around a more constructive view on earnings power, supported by exchange trends, Medicare Advantage performance, and early signs of Medicaid margin recovery, while still flagging several execution and policy risks that could affect valuation.Uppdatering av berättelse • Jun 29
CNC: Medicaid Margin Recovery And Cost Actions Will Support Balanced Outlook
Centene's analyst fair value estimate has moved from about $54.94 to roughly $61.83 as analysts factor in Medicaid margin recovery, a more stable policy backdrop for managed care, and updated earnings models that reflect recent Q1 trends and revised sector price targets. Analyst Commentary Recent research on Centene clusters around two themes: improving confidence in Medicaid and Marketplace margins, and a debate over how much of that recovery is already reflected in the stock's valuation.Analysartikel • Jun 19
Centene (CNC) Stock Could Be 11% Overvalued After Employee Buyout Offer
Centene (CNC) stock is in focus after the company moved to offer voluntary buyouts to most employees, a cost reduction step tied to weaker health plan membership, especially in Affordable Care Act marketplace products. See our latest analysis for Centene. Despite the recent buyout announcement and a sharp pullback of nearly 4% on the day it was reported, Centene’s share price has a 90 day share price return of 77.38% and a 1 year total shareholder return of 10.64%. However, 3 and 5 year total...
Uppdatering av berättelse • Jun 15
CNC: Medicaid Margin Recovery And Stable Policy Backdrop Will Support Future Earnings
Centene's analyst fair value estimate has been updated from $60.51 to $80.00. This reflects a broad series of higher Street price targets as analysts highlight a more stable managed care policy backdrop, margin recovery potential, and evidence of muted medical cost trends and softer utilization across the sector.Uppdatering av berättelse • Jun 01
CNC: Medicaid Margin Recovery Expectations Will Eventually Disappoint Current Optimism
Narrative Update Overview The analyst fair value estimate for Centene has moved from $32.00 to $40.00 as analysts factor in improving margin recovery expectations across government programs, steadier commercial trends, and a modestly higher assumed future P/E multiple that aligns with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Centene has shifted toward a more constructive stance, with multiple firms lifting price targets and, in some cases, upgrading ratings.Uppdatering av berättelse • May 16
CNC: Margin Recovery Efforts Will Offset Policy And Exchange Uncertainty
Centene's updated analyst price target moves from $43.47 to $54.94 as analysts factor in slightly higher revenue growth assumptions, a higher forward P/E multiple, and recent price target increases and upgrades across several research firms, balanced by some ongoing margin concerns. Analyst Commentary Recent research updates on Centene show a mix of optimism on the earnings and margin recovery path alongside caution about Medicaid and exchange exposure.Uppdatering av berättelse • Apr 29
CNC: Policy And Exchange Uncertainty Will Pressure Margins And Constrain Upside
Analysts have trimmed the fair value estimate for Centene to $43.47 from $44.18, reflecting updated views on revenue growth, margin potential, and a lower expected future P/E multiple, even as several recent price target revisions highlight ongoing debate around the stock. Analyst Commentary Recent Street research paints a mixed picture for Centene, with several firms adjusting price targets and ratings as they reassess the company after Q4 results, updated guidance, and regulatory developments.Uppdatering av berättelse • Apr 15
CNC: Medicaid Margins In 2026 Will Underpin Future Earnings Power
Centene's updated analyst price targets show only a modest reduction in implied fair value to about $60.51, as analysts factor in slightly better revenue growth and margins while tempering expectations with lower assumed P/E multiples and continued concern about margin pressure and exchange and Medicaid visibility. Analyst Commentary Recent research on Centene points to a mixed backdrop, but with a clear group of bullish analysts highlighting valuation support, execution on margins, and potential growth from policy and rate decisions.Uppdatering av berättelse • Apr 01
CNC: Government Program Margins In 2026 Will Support Future Earnings Power
Centene's updated analyst price targets show a modest downward reset of about $4 across several firms to a range of roughly $32 to $49, with analysts citing recalibrated valuation multiples, ongoing Medicaid and exchange visibility questions, and mixed readthroughs from recent Q4 results and policy headlines. Analyst Commentary Recent research shows a split view on Centene, with some firms trimming targets and others lifting them, but the common thread is a focus on how Medicaid, exchange membership, and Q4 execution shape the risk and reward profile from here.Uppdatering av berättelse • Mar 18
CNC: Government Managed Care Recovery In 2026 Will Support Future Earnings Power
Narrative Update Centene's implied fair value estimate has edged lower to about $60.89 from $62.81 as analysts recalibrated price targets. This reflects slightly softer growth and margin assumptions and a mix of recent target cuts and trims in valuation multiples across the group.Uppdatering av berättelse • Mar 04
CNC: Medicaid And Exchange Uncertainty Will Pressure Margins Despite 2026 EPS Guidance
Analysts have nudged their average price targets for Centene higher into a $43 to $59 range, pointing to margin improvement efforts, potential earnings power across segments, and sector recovery themes, even as they flag ongoing uncertainty around Medicaid and exchange visibility. Analyst Commentary Recent research on Centene shows a mix of optimism around margin potential and earnings power, alongside pointed concerns about execution risks in key government programs.Uppdatering av berättelse • Feb 17
CNC: Policy Uncertainty And Margin Recovery Prospects Will Shape Balanced Outlook
Analysts have lifted their average price target on Centene by about $3 to roughly $44, citing updated views on fair value, slightly higher expected profit margins and P/E, and ongoing research that points to potential margin recovery in government managed care despite recent CMS related concerns. Analyst Commentary Recent research on Centene reflects a mix of optimism around long term earnings power in government managed care and caution around policy and utilization risks that could affect how quickly that potential is realized.Uppdatering av berättelse • Feb 03
CNC: CMS Rate Pressure And Medicaid Uncertainty Will Restrain Future Earnings Recovery
Analysts have lifted their price targets on Centene into a US$43 to US$59 range, citing updated views on government managed care earnings potential and recently softer utilization trends, even as broader commentary highlights ongoing policy and Medicaid uncertainty for the sector. Analyst Commentary Recent research on Centene sits against a mixed backdrop for government managed care, with several firms highlighting both potential earnings recovery drivers and ongoing policy and contract risks.Uppdatering av berättelse • Jan 20
CNC: Government Managed Care Policy Tailwinds Will Support Future Earnings Power
Analysts have lifted their fair value estimate for Centene from about $54.65 to roughly $62.81, citing updated views on discount rates, revenue growth, margins, and future P/E following recent price target hikes and sector commentary around government managed care and the "Great Healthcare Plan." Analyst Commentary Bullish analysts are highlighting a mix of policy tailwinds, product positioning, and company specific execution as reasons to revisit Centene's valuation. Recent research focuses on how government managed care, Medicare Advantage rate discussions, and the "Great Healthcare Plan" could influence earnings power and the multiple investors are willing to pay.Uppdatering av berättelse • Jan 06
CNC: Marketplace Margin Recovery And Medicaid Pressures Will Shape Balanced Outlook
Analysts have raised their implied fair value estimate for Centene to about US$41 from roughly US$40, reflecting a mix of higher price targets tied to recent earnings beats and margin recovery expectations in Marketplace and Medicaid, partially balanced by concerns around Medicaid trends and contract losses. Analyst Commentary Recent Street research on Centene reflects a split view, with some analysts focusing on earnings power from margin recovery and others highlighting ongoing risks in Medicaid and selected contracts.Uppdatering av berättelse • Dec 19
CNC: Medicaid Margin Pressures Will Likely Cap Earnings Recovery Ahead
Analysts have raised their fair value estimate for Centene to $32 from $24, citing improving margin visibility, stronger than expected Q3 results, and a more constructive long term earnings trajectory despite near term Medicaid and contract headwinds. Analyst Commentary Street research following Centene's Q3 earnings has been mixed, with several firms lifting price targets on the back of stronger profitability trends while others caution that EPS visibility remains constrained by Medicaid and Marketplace uncertainties.Uppdatering av berättelse • Dec 05
CNC: Marketplace And Medicaid Margin Normalization Will Offset Policy And Contract Headwinds
Analysts have modestly raised their price target on Centene to $39.94 from $39.41, citing improved profit margin visibility and expectations for continued EPS growth as Marketplace and Medicaid margins recover, despite lingering near-term Medicaid pressures. Analyst Commentary Street research on Centene has become more polarized, with several bullish analysts lifting price targets into the mid 40s on the back of Q3 outperformance and clearer earnings visibility, while a cohort of more cautious voices highlight lingering Medicaid and Star rating risks that could constrain valuation multiple expansion.Uppdatering av berättelse • Nov 21
CNC: Margin Recovery In Medicaid And Marketplace Will Drive 2026 Earnings Upside
Centene's analyst price target has increased by $5.59 to $45.00, as analysts expect margin recovery in the Marketplace and Medicaid segments to drive accelerated earnings growth, despite ongoing near-term pressures. Analyst Commentary Recent research coverage of Centene highlights a mix of positive and negative outlooks, with analyst views divided over the company’s near- and medium-term trajectory.Uppdatering av berättelse • Nov 06
CNC: Medicaid Margin Stability And 26% ACA Premium Hike Will Shape 2026 Prospects
Centene’s analyst price target has been raised from $36 to approximately $39.76 per share. Analysts cite improving Medicaid profitability and stronger earnings guidance as key drivers for the upward revision.Uppdatering av berättelse • Oct 22
Analysts Lift Centene Price Target on Margin Recovery but Warn of Lasting Sector Headwinds
Centene's analyst fair value target has been increased from $34.63 to $36.00. Analysts highlight improving margin visibility and constructive EPS guidance updates as key factors supporting the upward revision.Uppdatering av berättelse • Oct 08
Medicaid And Medicare Advantage Will Expand Health Care Access
Centene's analyst price target increased from $33.94 to $34.63, as analysts cited stable EPS guidance, anticipated Medicaid margin improvement, and a constructive outlook for Marketplace rates as supporting factors for the revision. Analyst Commentary Recent analyst research on Centene reflects a full spectrum of perspectives, as experts weigh strong execution signals against ongoing uncertainties in the managed care and healthcare exchange landscape.Uppdatering av berättelse • Sep 19
Medicaid And Medicare Advantage Will Expand Health Care Access
Centene's modest price target increase reflects mixed analyst sentiment, with optimism around reaffirmed FY25 EPS guidance and Medicaid margin improvements tempered by concerns over ongoing Medicaid and marketplace pressures, regulatory risks, and reduced long-term earnings visibility, resulting in a slight upward revision of fair value to $33.94. Analyst Commentary Bullish analysts cite reaffirmation of FY25 adjusted EPS guidance and constructive commentary on Medicaid margin improvement, ACA Marketplace rate refiling, and Stars performance as supporting recent price target raises.Analysartikel • Sep 12
Centene Corporation's (NYSE:CNC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
Centene Corporation ( NYSE:CNC ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...Uppdatering av berättelse • Sep 04
Medicaid And Medicare Advantage Will Expand Health Care Access
Centene’s analyst price target remains at $34.56 as ongoing macro and regulatory uncertainty, elevated Medicaid cost trends, and withdrawn 2025 EPS guidance have driven increased caution and reduced forward earnings visibility. Analyst Commentary Persistent macro uncertainty and regulatory volatility in the healthcare exchange (ACA Marketplace) and Medicaid markets are driving cautious outlooks, especially due to potential disenrollment, risk pool degradation, and rate/trend volatility stemming from legislative changes and the expiration of enhanced APTCs. Centene’s withdrawal of FY2025 EPS guidance, prompted by incorrect Marketplace risk-adjustment assumptions and elevated Medicaid cost trends, has resulted in significant downward revisions to earnings estimates for the next three years.Seeking Alpha • Mar 26
Centene: A Leader In Government-Sponsored Insurance And Its Prospects
Summary Centene's business transformation and strategic focus on core segments have led to increased operational marginality, despite losing 3.3 million Medicaid customers in 2024. I assign a "Buy" rating to Centene, with a fair valuation of $73 per share, indicating a 27% potential increase from the current price. The company’s competitive advantage lies in its focus on Medicaid and Medicare, but it faces risks from regulatory changes and strong competition. Centene's prospects are bolstered by demographic trends, Medicaid privatization, and ACA Marketplace demand, with expected improvements in cash flow and profitability. Read the full article on Seeking AlphaSeeking Alpha • Mar 18
Centene Corporation Is Resilient And Will Thrive
Summary Centene Corporation is a buy opportunity under $60, with a strong valuation and momentum, despite market volatility and economic concerns. The company reported strong Q4 '24 results, with EPS of $0.80 and FY '24 EPS of $7.17, and management raised 2025 revenue guidance by $4 billion. Risks include potential Medicaid and Medicare enrollment cuts, program pullbacks, and cash flow concerns for the company, but we expect management to navigate these challenges. Insiders and hedge funds are investing, indicating confidence in Centene's resilience and growth potential, with a target price of around $72. Read the full article on Seeking AlphaSeeking Alpha • Jan 02
Centene: Attractive Risk-Reward For A Growing Company At A Value Price
Summary Centene reported strong Q3’24 results, beating revenue expectations by $4.13 billion and achieving EPS of $1.62, driven by Medicaid rate increases and membership growth. Key highlights from the quarter include successful Medicaid reprocurements, improved 2025 Medicare Advantage star ratings, and advancements in AI for operational efficiency, positioning Centene for long-term growth. Despite some leverage, Centene's investment-grade rating and attractive debt maturities suggest financial stability, with a promising outlook for EPS growth and Medicare revenue. Insider buying and undervaluation, with Centene trading at around 10x earnings, indicate confidence in the company's future despite Medicaid redetermination and regulatory risks. Read the full article on Seeking AlphaSeeking Alpha • Oct 22
Centene: Should Have Followed My Original Thesis, But A Buy For Q3 2024
Summary Centene, a leading health insurer, shows strong fundamentals and growth despite sector challenges, making it a "Buy" at a target price of $70/share. The company’s 2Q24 results indicate robust earnings growth and increasing membership, contrasting with peers like Humana, which face significant declines. Centene's valuation at $61/share with a P/E of 9x is attractive, projecting a potential 27.17% annualized upside until 2026. Despite lacking a dividend, Centene's stability and growth prospects in government programs and managed healthcare segments justify a conservative investment approach. Read the full article on Seeking AlphaAktieägarnas avkastning
| CNC | US Healthcare | US Marknad | |
|---|---|---|---|
| 7D | 8.4% | -1.9% | 5.5% |
| 1Y | 165.7% | 43.6% | 20.8% |
Avkastning vs industri: CNC översteg US Healthcare branschen som gav 43.6 % under det senaste året.
Avkastning vs Marknaden: CNC översteg US marknaden som gav 20.8 % under det senaste året.
Prisvolatilitet
| CNC volatility | |
|---|---|
| CNC Average Weekly Movement | 5.6% |
| Healthcare Industry Average Movement | 7.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: CNC har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: CNC s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1984 | 61,100 | Sarah London | www.centene.com |
Centene Corporation är ett managed care-företag som tillhandahåller program och tjänster till underförsäkrade familjer och kommersiella organisationer i USA. Verksamheten bedrivs genom fyra segment: Medicaid, Medicare, Commercial och Other. Segmentet Medicaid erbjuder tillfälligt stöd till behövande familjer, utvidgning av Medicaid, sjukförsäkringsprogram för äldre, blinda eller funktionshindrade och barn, samt långtidstjänster och stöd, fosterhem och Medicare-Medicaid-planer.
Centene Corporation Sammanfattning av grunderna
| CNC grundläggande statistik | |
|---|---|
| Börsvärde | US$31.65b |
| Vinst(TTM) | -US$5.10b |
| Intäkter(TTM) | US$180.30b |
0.2x
P/S-förhållande-6.5x
P/E-förhållandeÄr CNC övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| CNC resultaträkning (TTM) | |
|---|---|
| Intäkter | US$180.30b |
| Kostnad för intäkter | US$159.72b |
| Bruttovinst | US$20.58b |
| Övriga kostnader | US$25.68b |
| Intäkter | -US$5.10b |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
Oct 27, 2026
| Vinst per aktie (EPS) | -10.32 |
| Bruttomarginal | 11.41% |
| Nettovinstmarginal | -2.83% |
| Skuld/egenkapitalförhållande | 71.1% |
Hur har CNC utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/05 11:09 |
| Aktiekurs vid dagens slut | 2026/08/05 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Centene Corporation bevakas av 33 analytiker. 14 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | Argus Research Company |
| Hua Ha | Baird |
| Andrew Mok | Barclays |